Top Line: Is selective post-operative chemoradiation non-inferior to neoadjuvant chemoradiation for locally advanced rectal cancer?
The Study: This randomized trial from China sought to determine if primary surgery and selective adjuvant chemoradiation was non-inferior to standard neoadjuvant CRT followed by surgery for locally advanced rectal cancer. Yes, very similar trials from a couple decades ago established that neoadjuvant CRT had superior local control and less toxicity than adjuvant CRT. The difference here is to use MRI to identify a population with low risk of recurrence with surgery alone, and to use adjuvant therapy only for those with adverse pathology. It included 275 patients with T3-4aN0 or T1-4aN1-2 rectal adenocarcinoma, an inferior tumor edge 6-12cm from the anal verge, and gross primary or nodal disease >1mm from the mesorectal fascia–all based on preoperative MRI. They were randomized to receive nCRT (50.4 Gy in 28 fractions and concurrent capecitabine followed by CapeOx) or upfront surgery followed by adjuvant chemo and CRT when there was tumor within 1mm of the circumferential resection margin. The positive CRM rate was relatively low in each arm (1.5% upfront surgery v 0.77% CRT), and just 9.2% of surgery patients received adjuvant CRT. Statistically, the results were confusing. The short version is that the trial was stopped due to a significantly higher rate of local recurrence in the upfront surgery arm (4.3% v 0%). The rate of DFS at 3 years was 81.1% v 86.6%, but the difference still fell within the massive 15% non-inferiority margin set out in the trial design.
TBL: This randomized trial found a higher rate of local recurrence (4% v 0%) with surgery and selective adjuvant CRT for patients with mid-to-upper rectal cancer and negative circumferential margin on MRI. | Li, Int J Radiat Oncol Biol Phys 2024
The Study: This randomized trial from China sought to determine if primary surgery and selective adjuvant chemoradiation was non-inferior to standard neoadjuvant CRT followed by surgery for locally advanced rectal cancer. Yes, very similar trials from a couple decades ago established that neoadjuvant CRT had superior local control and less toxicity than adjuvant CRT. The difference here is to use MRI to identify a population with low risk of recurrence with surgery alone, and to use adjuvant therapy only for those with adverse pathology. It included 275 patients with T3-4aN0 or T1-4aN1-2 rectal adenocarcinoma, an inferior tumor edge 6-12cm from the anal verge, and gross primary or nodal disease >1mm from the mesorectal fascia–all based on preoperative MRI. They were randomized to receive nCRT (50.4 Gy in 28 fractions and concurrent capecitabine followed by CapeOx) or upfront surgery followed by adjuvant chemo and CRT when there was tumor within 1mm of the circumferential resection margin. The positive CRM rate was relatively low in each arm (1.5% upfront surgery v 0.77% CRT), and just 9.2% of surgery patients received adjuvant CRT. Statistically, the results were confusing. The short version is that the trial was stopped due to a significantly higher rate of local recurrence in the upfront surgery arm (4.3% v 0%). The rate of DFS at 3 years was 81.1% v 86.6%, but the difference still fell within the massive 15% non-inferiority margin set out in the trial design.
TBL: This randomized trial found a higher rate of local recurrence (4% v 0%) with surgery and selective adjuvant CRT for patients with mid-to-upper rectal cancer and negative circumferential margin on MRI. | Li, Int J Radiat Oncol Biol Phys 2024

